美國HemoGenix  www.hemogenix.com
美國HemoGenix公司成立于2000年.是一家研發(fā)型公司，在造血細(xì)胞血毒性檢測(cè)領(lǐng)域處于世界領(lǐng)先地位。HemoGenix公司開發(fā)的HALOTM（Hemotoxicity Assays via Luminescence Output）技術(shù)平臺(tái)（專利技術(shù)），沒有采用經(jīng)典的集落形成評(píng)價(jià)方法，而是根據(jù)培養(yǎng)細(xì)胞中的ATP含量（使用發(fā)光檢測(cè)法）的變化，來評(píng)價(jià)造血細(xì)胞的增生能力或化合物對(duì)造血細(xì)胞的毒副作用。ATP含量檢測(cè)在96孔板中進(jìn)行，高通量、高效、快速。
HemoGenix公司推出的HALO Basic Research Kit Platform，種類多達(dá)360余種。使用這些Kit可以檢測(cè)來自五個(gè)物種的（人、靈長類、豬、狗、鼠），不同來源的（脊髓、臍帶血、外周血）14種不同的干細(xì)胞、祖細(xì)胞，以及前體細(xì)胞種群。此外，使用這些Kit，也可以實(shí)現(xiàn)兩種、三種、四種，甚至八種群細(xì)胞的同時(shí)檢測(cè)。
HALO Stem and Progenitor Cell Quality Control（HALO SPC QC）Kit Platform是專門為分離移植用造血干細(xì)胞的實(shí)驗(yàn)室及臍帶血庫設(shè)計(jì)的，一個(gè)96孔板可同時(shí)檢出7種群細(xì)胞（HPP-SP、CFC-GEMM、BFU-E、GM-CFC、T-CFC、B-CFC），根據(jù)這7種群細(xì)胞的檢出情況，可判斷待移植細(xì)胞的質(zhì)量。
HALO Predictive Hemotoxicity Kit Platform是在HALO SPC QC Kit Platform基礎(chǔ)上設(shè)計(jì)的，可以預(yù)測(cè)不同劑量的藥物對(duì)不同種群造血細(xì)胞的作用情況，非常適用于候選新藥的篩選。
以上Kit中均含有細(xì)胞培養(yǎng)所需的試劑：甲基纖維素、血清組分、造血細(xì)胞生長因子，以及ATP檢測(cè)所需試劑，只要備有能檢測(cè)96孔板的發(fā)光計(jì)即可對(duì)靶細(xì)胞（造血細(xì)胞、研究者自備）實(shí)施監(jiān)測(cè)。另有一類Kit中不含有造血細(xì)胞生長因子，以滿足用戶非增生目的研究的需要或用戶使用自己的造血因子進(jìn)行實(shí)驗(yàn)。
此外，HemoGenix公司還提供另一種類型的Kit：The OxyFLOW Platform，該試劑盒可使用流式細(xì)胞儀檢測(cè)人及其他哺乳動(dòng)物外周血、脊髓、臍帶血中的DNA損傷情況。

HemoGenix® was founded in March 2000 by Ivan N. Rich, PhD, an internationally recognized researcher in the field of developmental, experimental and applied clinical hematology. HemoGenix® was formed as a Contract Research Service Laboratory for the biotechnology and pharmaceutical industry as the only company in the world primarily specializing in stem cell hemotoxicity testing. Initially, this was performed using techniques, such as the colony-forming assays. However, it was soon realized that these assays had many disadvantages (discussed elsewhere on this website) that made it a bad technique for the industry. With the help of a Phase I SBIR grant awarded from the National Cancer Institute (NCI) in October 2001, HemoGenix® began developing, what is now the HALO® Platform, in January 2002. By March 2002, The HALO® Platform was launched as a contract service at the Society of Toxicology meeting in Nashville, TN. A Phase II SBIR grant from the NCI in Spring 2003 allowed HemoGenix® to begin the necessary validation of the HALO® Platform.
In September 2003, HemoGenix® relocated from Columbia, South Carolina to Colorado Springs, Colorado in order to expand the company, begin the HALO® validation procedure and initiate production of the HALO® Kit Platform.
The HALO® Research Kit Platform was launched at the American Society of Hematology in December 2003. At the Society of Toxicology meeting in 2004, the first HALO® Hemotoxicity Kits and the OxyFLOW™ Platform were introduced. In December 2004, at the American Society of Hematology, the HALO® Stem and Progenitor Cell - Quality Control (SPC-QC) Kits and the LUMENESC™ Kit Platform to detect Mesenchymal Stem Cells (MSC) were introduced. In March 2005, the HALO® Predictive Hemotoxicity Platform was unveiled at the Society of Toxicology. Following this, HemoGenix®, launched the LumiSTEM™ Platform and introduced the concept of "In Vitro Cross-Platform Comparative Toxicity". This was based on the ability of both LUMENESC™ and LumiSTEM™ to utilize a 384-well plate format. What was missing was the 384-well plate format for the HALO® Platform. This was introduced as the HALO®-96 SEC and and HALO®-384 HT both of which allow fully automated and high-throughput capability to detect and measure the response of lympho-hematopoietic cells. Since relocating to Colorado Springs, HemoGenix®, Inc has increased its Assay Kit Catalog to over 1,000 different items. It produces and sells HALO®, LUMENESC™, LumiSTEM™ and OxyFLOW™ Kits all over the world to biotechnology and pharmaceutical companies and academic institutions.
As of January 1, 2004, HemoGenix® converted from and LLC to an "S" Corporation.